Literature DB >> 16220489

Estimation in flexible two stage designs.

Werner Brannath1, Franz König, Peter Bauer.   

Abstract

Adaptive test designs for clinical trials allow for a wide range of data driven design adaptations using all information gathered until an interim analysis. The basic principle is to use a test statistics which is invariant with respect to the design adaptations under the null hypothesis. This allows for a control of the type I error rate for the primary hypothesis even for adaptations not specified a priori in the study protocol. Estimation is usually another important part of a clinical trial, however, is more difficult in adaptive designs. In this research paper we give an overview of point and interval estimates for flexible designs and compare methods for typical sample size rules. We also make some proposals for confidence intervals which have nominal coverage probability also after an unforeseen design adaptation and which contain the maximum likelihood estimate and the usual unadjusted confidence interval. Copyright 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2006        PMID: 16220489     DOI: 10.1002/sim.2258

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  12 in total

1.  The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMJ       Date:  2020-06-17

2.  Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment.

Authors:  M Rosenblum; M J Van der Laan
Journal:  Biometrika       Date:  2011-12       Impact factor: 2.445

3.  Asymptotic properties of maximum likelihood estimators with sample size recalculation.

Authors:  Sergey Tarima; Nancy Flournoy
Journal:  Stat Pap (Berl)       Date:  2019-02-28       Impact factor: 2.234

4.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

5.  Distribution Theory Following Blinded and Unblinded Sample Size Re-estimation under Parametric Models.

Authors:  Sergey Tarima; Nancy Flournoy
Journal:  Commun Stat Simul Comput       Date:  2019-11-22       Impact factor: 1.162

6.  Bias induced by adaptive dose-finding designs.

Authors:  Nancy Flournoy; Assaf P Oron
Journal:  J Appl Stat       Date:  2019-08-01       Impact factor: 1.416

7.  Confidence intervals for the selected population in randomized trials that adapt the population enrolled.

Authors:  Michael Rosenblum
Journal:  Biom J       Date:  2013-04-03       Impact factor: 2.207

8.  Maximum inflation of the type 1 error rate when sample size and allocation rate are adapted in a pre-planned interim look.

Authors:  Alexandra C Graf; Peter Bauer
Journal:  Stat Med       Date:  2011-04-15       Impact factor: 2.373

9.  The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  Trials       Date:  2020-06-17       Impact factor: 2.279

10.  The statistical analysis of a clinical trial when a protocol amendment changed the inclusion criteria.

Authors:  Christian Lösch; Markus Neuhäuser
Journal:  BMC Med Res Methodol       Date:  2008-04-08       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.